Classification, epidemiology and clinical subgrouping of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis

Nephrology Dialysis Transplantation

Volumn 30, Issue , 2015, Pages i14-i22

  Watts, Richard A ^a   Mahr, Alfred ^b   Mohammad, Aladdin J ^c,d   Gatenby, Paul ^e   Basu, Neil ^f   Flores Suárez, Luis Felipe ^g  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b SAINT LOUIS HOSPITAL   (France)

^c LUND UNIVERSITY   (Sweden)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

^e The Australian National University   (Australia)

^f UNIVERSITY OF ABERDEEN   (United Kingdom)

^g INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

Author keywords

ANCA; classification; epidemiology; vasculitis

Indexed keywords

ANCA ASSOCIATED VASCULITIS; CASE CONTROL STUDY; DISEASE CLASSIFICATION; EPIDEMIOLOGICAL DATA; HOSPITAL CARE; HUMAN; INCIDENCE; POPULATION SIZE; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RARE DISEASE; RETROSPECTIVE STUDY; REVIEW; RISK FACTOR; SECONDARY HEALTH CARE; STATISTICAL ANALYSIS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CLASSIFICATION; EUROPE; PATHOLOGY;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; EUROPE; HUMANS; INCIDENCE;

EID: 84926615364     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv022     Document Type: Review

References (92)

1. Hagen EC, Andrassy K, Csernok E et al. Development and standardization of solid phase assays for the detection of anti-neutrophil cytoplasmic antibodies (ANCA). A report on the second phase of an international cooperative study on the standardization of ANCA assays. J Immunol Methods. 1996; 196: 1-15
2. Hunder GG, Arend WP, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction. Arthritis Rheum. 1990; 33: 1065-1067
3. Leavitt RY, Fauci AS, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum. 1990; 33: 1101-1107
4. Masi AT, Hunder GG, Lie JT et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990; 33: 1094-1100
5. Lightfoot RW, Michel BA, Bloch DA et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum. 1990; 33: 1088-1093
6. Watts RA, Suppiah R, Merkel PA et al. Systemic vasculitis-is it time to reclassify? Rheumatology (Oxford). 2011; 50: 643-645.
7. Van der Woude FJ, Rasmussen N, Lobatto S et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet. 1985; 1: 425-429
8. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculit-ides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37: 187-192
9. Jennette J, Falk R, Bacon P et al. 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum. 2013; 65: 1-11
10. Watts R, Lane S, Hanslik T et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis. 2007; 66: 222-227
11. Liu L-J, Chen M, Yu F et al. Evaluation of a new algorithm in classification of systemic vasculitis. Rheumatology (Oxford). 2008; 47: 708-712
12. Waller R, Ahmed A, Patel I et al. Update on the classification of vasculitis. Best Pract Res Clin Rheumatol. 2013; 27: 3-17
13. Craven A, Robson J, Ponte C et al. ACR/EULAR-endorsed study to develop diagnostic and classification criteria for vasculitis (DCVAS). Clinical and Experimental Nephrology. 2013; 17: 619-621
14. Andrews M, Edmunds M, Campbell A et al. Systemic vasculitis in the 1980s-is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J R Coll Physicians Lond. 1990; 24: 284-288.
15. Watts RA, Mooney J, Skinner J et al. The contrasting epidemiology of granulomatosis with polyangiitis (Wegener's) and microscopic polyangiitis. Rheumatology. 2012; 51: 926-931
16. Fujimoto S, Watts Ra, Kobayashi S et al. Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U.K. Rheumatology (Oxford). 2011; 50: 1916-1920
17. Watts RA, Al-Taiar A, Scott DGI et al. Prevalence and incidence of Wegener's granulomatosis in the UK general practice research database. Arthritis Rheum. 2009; 61: 1412-1416
18. Haugeberg G, Bie R, Bendvold A et al. Primary vasculitis in a Norwegian community hospital: a retrospective study. Clin Rheumatol. 1998; 17: 364-368
19. Koldingsnes W, Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum. 2000; 43: 2481-2487
20. Watts RA, Lane SE, Scott DG et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001; 60: 1156-1157
21. Knight A, Ekbom A, Brandt L et al. Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001. J Rheumatol. 2006; 33: 2060-2063
22. Mohammad AJ, Jacobsson LTH, Westman KWA et al. Incidence and survival rates in Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome and polyarteritis nodosa. Rheumatology (Oxford). 2009; 48: 1560-1565
23. Takala JH, Kautiainen H, Malmberg H et al. Incidence of Wegener's gran-ulomatosis in Finland 1981-2000. Clin Exp Rheumatol. 2008; 26(3 Suppl 49): S81-S85
24. Andrassy K, Küster S, Waldherr R et al. Rapidly progressive glomeruloneph-ritis: analysis of prevalence and clinical course. Nephron. 1991; 59: 206-212
25. Reinhold-Keller E, Herlyn K, Wagner-Bastmeyer R et al. Stable incidence of primary systemic vasculitides over five years: results from the German vasculitis register. Arthritis Rheum. 2005; 53: 93-99
26. Dadoniene J, Kirdaite G, Mackiewicz Z et al. Incidence of primary systemic vasculitides in Vilnius: a university hospital population based study. Ann Rheum Dis. 2005; 64: 335-336
27. Panagiotakis SH, Perysinakis GS, Kritikos H et al. The epidemiology of primary systemic vasculitides involving small vessels in Crete (southern Greece): a comparison of older versus younger adult patients. Clin Exp Rheumatol. 2009; 27: 409-415
28. Gonzalez-Gay Ma, Garcia-Porrua C, Guerrero J et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum. 2003; 49: 388-393
29. Romero-Gomez C, Aguilar-Garcia J, Garcia de Lucas M et al. Epidemiol-gic study of primary systemic vasculitis in adults in South Eastern Spain. Presse Med. 2013; 42: 705
30. Catanaso M, Macchioni P, Boiardi L et al. Epidemiology of granulomatosis with polyangiitis (Wegner's granulomatosis) in Northern Italy: a 15-year population based study. Semin Arthritis Rheum. 2014; 44: 202-207
31. Faurschou M, Helleberg M, Obel N et al. Incidence of granulomatosis with polyangiitis (Wegener's) in Greenland and the Faroe Islands: epidemiology of an ANCA-associated vasculitic syndrome in two ethnically distinct populations in the North Atlantic area. Clin Exp Rheumatol. 2013; 31(1 Suppl 75): S52-S55
32. Vinit J, Muller G, Bielefeld P et al. Churg-Strauss syndrome: retrospective study in Burgundian population in France in past 10 years. Rheumatol Int. 2011; 31: 587-593
33. Pamuk Ö, Dönmez S, Calayir G. The Incidences of anti-neutrophil cyto-plasmic antibody-associated vasculitis in Northeastern part of Turkey. Ann Rheum Dis. 2013; 72(Suppl 3): 638
34. Zeft AS, Schlesinger M, Keenan H et al. Wegener's granulomatosis and environmental factors in Western Montana. Rheumatology Reports. 2010. p. e8
35. Anderson K, Klassen J, Stewart SA et al. Does geographic location affect incidence of ANCA-associated renal vasculitis in northern Saskatchewan, Canada? Rheumatology (Oxford). 2013; 52: 1840-1844
36. Sánchez Torres A, Acevedo Vásquez E, Sánchez Schwartz C et al. Epide-miología de las vasculitis sistémicas primarias en una población latinoa-mericana. Reumatologia. 2005; 21: 145-150
37. Hissaria P, Cai FZJ, Ahern M et al. Wegener's granulomatosis: epidemio-logical and clinical features in a South Australian study. Intern Med J. 2008; 38: 776-780
38. Ormerod AS, Cook MC. Epidemiology of primary systemic vasculitis in the Australian Capital Territory and south-eastern New South Wales. Intern Med J. 2008; 38: 816-823
39. O'Donnell JL, Stevanovic VR, Frampton C et al. Wegener's granulomato-sis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern Med J. 2007; 37: 242-246
40. Wu C-S, Hsieh C-J, Peng Y-S et al. Antineutrophil cytoplasmic antibody-associated vasculitis in Taiwan: a hospital-based study with reference to the population-based National Health Insurance Database. J Microbiol Immunol Infect. 2014; doi: 10.1016/j.jmii.2013.12.006
41. el-Reshaid K, Kapoor MM, El-Reshaid W et al. The spectrum of renal disease associated with microscopic polyangiitis and classic polyarteritis nodosa in Kuwait. Nephrol Dial Transplant. 1997; 12: 1874-1882
42. Fauci A, Haynes B, Katz P et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983; 98: 76-85
43. Mahr A, Guillevin L, Poissonnet M et al. Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000: a capture-recapture estimate. Arthritis Rheum. 2004; 51: 92-99
44. Reinhold-Keller E, Zeidler a, Gutfleisch J et al. Giant cell arteritis is more prevalent in urban than in rural populations: results of an epidemiological study of primary systemic vasculitides in Germany. Rheumatology (Oxford). 2000; 39: 1396-1402
45. Herlyn K, Buckert F, Gross WL et al. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology (Oxford). 2014; 53: 882-889
46. Eaton WW, Rose NR, Kalaydjian A et al. Epidemiology of autoimmune diseases in Denmark. J Autoimmun. 2007; 29: 1-9
47. Mohammad AJ, Jacobsson LTH, Mahr AD et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford). 2007; 46: 1329-1337
48. Gibson A, Stamp LK, Chapman PT et al. The epidemiology of Wegener's granulomatosis and microscopic polyangiitis in a Southern Hemisphere region. Rheumatology (Oxford). 2006; 45: 624-628
49. Fujimoto S, Uezono S, Hisanaga S et al. Incidence of ANCA-associated primary renal vasculitis in the Miyazaki Prefecture: the first population-based, retrospective, epidemiologic survey in Japan. Clin J Am Soc Nephrol. 2006; 1: 1016-1022
50. Sada K-E, Amano K, Uehara R et al. A nationwide survey on the epidemiology and clinical features of eosinophilic granulomatosis with polyangiitis (Churg-Strauss) in Japan. Mod Rheumatol. 2014; 24: 640-644
51. Cotch MF, Hoffman GS, Yerg DE et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996; 39: 87-92
52. Lhote F, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical aspects and treatment. Rheum Dis Clin North Am. 1995; 21: 911-947
53. Watts RA, Lane SE, Bentham G et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum. 2000; 43: 414-419
54. Cao Y, Schmitz JL, Yang J et al. DRB1∗15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol. 2011; 22: 1161-1167
55. Watts RA, MacGregor AJ, Mackie SL. HLA allele variation as a potential explanation for the geographical distribution of granulomatosis with poly-angiitis. Rheumatology (Oxford). 2015; 54: 359-362
56. Tian C, Kosoy R, Nassir R et al. European population genetic substructure: further definition of ancestry informative markers for distinguishing among diverse European ethnic groups. Mol Med. 2009; 15: 371-383
57. Chung SA, Tian C, Taylor KE et al. European population substructure is associated with mucocutaneous manifestations and autoantibody production in systemic lupus erythematosus. Arthritis Rheum. 2009; 60: 2448-2456
58. Lyons Pa, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-associated vasculitis. N Engl J Med. 2012; 367: 214-223
59. Tidman M, Olander R, Svalander C et al. Patients hospitalized because of small vessel vasculitides with renal involvement in the period 1975-95: organ involvement, anti-neutrophil cytoplasmic antibodies patterns, seasonal attack rates and fluctuation of annual frequencies. J Intern Med. 1998; 244: 133-141
60. Mahr A, Artigues N, Coste J et al. Seasonal variations in onset of Wegener's granulomatosis: increased in summer? J Rheumatol. 2006; 33: 1615-1622
61. Watts RA, Gonzalez-Gay MA, Lane SE et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann Rheum Dis. 2001; 60: 170-172
62. Chen M, Kallenberg CGM. The environment, geoepidemiology and ANCA-associated vasculitides. Autoimmun Rev. 2010; 9: A293-A298
63. Popa ER, Tervaert JWC. The relation between Staphylococcus aureus and Wegener's granulomatosis: current knowledge and future directions. Intern Med. 2003; 42: 771-780
64. Stegeman CA, Tervaert JW, de Jong PE et al. Trimethoprim-sulfameth-oxazole (co-trimoxazole) for the prevention of relapses of Wegener's gran-ulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med. 1996; 335: 16-20
65. Rainsford KD. Side-effects of anti-inflammatory drugs IV. The Proceedings of the IVth International Meeting on Side Effects of Anti-inflammatory Drugs, held in Sheffield, UK, 7-9 August 1995. Dordrecht; London: Kluwer Academic, 1997.
66. Nickerson A, Marik PE. Life-threatening ANCA-positive vasculitis associated with rickettsial infection. BMJ Case Rep. 2012; 2012: doi: 10.1136/bcr.03.2012.5993
67. Fukasawa H, Hayashi M, Kinoshita N et al. Rapidly progressive glomer-ulonephritis associated with PR3-ANCA positive subacute bacterial endocarditis. Intern Med. 2012; 51: 2587-2590
68. Xu P, Lin S, Wei L et al. Antineutrophil cytoplasmic antibody-associated vasculitis associated with Epstein-Barr virus infection: a case report and review of the literature. Infection. 2014; 42: 591-594
69. Kain R, Exner M, Brandes R et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med. 2008; 14: 1088-1096
70. Roth AJ, Brown MC, Smith RN et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glom-erulonephritis. J Am Soc Nephrol. 2012; 23: 545-555
71. Gatenby PA, Lucas RM, Engelsen O et al. Antineutrophil cytoplasmic antibody-associated vasculitides: could geographic patterns be explained by ambient ultraviolet radiation? Arthritis Rheum. 2009; 61: 1417-1424.
72. Ponsonby A-L, Lucas RM, van der Mei IAF. UVR, vitamin D and three autoimmune diseases-multiple sclerosis, type 1 diabetes, rheumatoid arthritis. Photochem Photobiol. 2005; 81: 1267-1275
73. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases: an update. Curr Opin Rheumatol. 2013; 25: 184-191
74. Gatenby P. The role of environmental factors in the pathogenesis of anti-neutrophil antibody associated vasculitis. Immunome Res. 2013; 9: 1-7
75. Steenland K. One agent, many diseases: exposure-response data and comparative risks of different outcomes following silica exposure. Am J Ind Med. 2005; 48: 16-23
76. Yashiro M, Muso E, Itoh-Ihara T et al. Significantly high regional morbidity of MPO-ANCA-related angitis and/or nephritis with respiratory tract involvement after the 1995 great earthquake in Kobe (Japan). Am J Kidney Dis. 2000; 35: 889-895
77. De Lind van Wijngaarden RAF, van Rijn L, Hagen EC et al. Hypotheses on the etiology of antineutrophil cytoplasmic autoantibody associated vas-culitis: the cause is hidden, but the result is known. Clin J Am Soc Nephrol. 2008; 3: 237-252
78. Lane SE, Watts RA, Bentham G et al. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum. 2003; 48: 814-823
79. Duna GF, Cotch MF, Galperin C et al. Wegener's granulomatosis: role of environmental exposures. Clin Exp Rheumatol. 1998; 16: 669-674
80. Yu F, Chen M, Gao Y et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis. 2007; 49: 607-614
81. Cuellar ML. Drug-induced vasculitis. Curr Rheumatol Rep. 2002; 4: 55-59
82. Pendergraft WF, Niles JL. Trojan horses: drug culprits associated with antineutrophil cytoplasmic autoantibody (ANCA) vasculitis. Curr Opin Rheumatol. 2014; 26: 42-49
83. Gao Y, Chen M, Ye H et al. The target antigens of antineutrophil cytoplas-mic antibodies (ANCA) induced by propylthiouracil. Int Immunophar-macol. 2007; 7: 55-60
84. Arnson Y, Shoenfeld Y, Amital H. Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun. 2010; 34: J258-J265
85. Haubitz M, Woywodt A, de Groot K et al. Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis. Ann Rheum Dis. 2005; 64: 1500-1502
86. Basu N, Mohammad A, Watts R et al. The effect of smoking on the clinical expression of ANCA-associated vasculitis. Arthritis Rheum. 2013; 65: S1192-3
87. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013; 17: 851-859
88. Fourlanos S, Harrison LC, Colman PG. The accelerator hypothesis and increasing incidence of type 1 diabetes. Curr Opin Endocrinol Diabetes Obes. 2008; 15: 321-325
89. Watts RA, Scott DGI. ANCA vasculitis: to lump or split?: Why we should study MPA and GPA separately. Rheumatology (Oxford). 2012; 25: 3-5
90. Millet A, Pederzoli-Ribeil M, Guillevin L et al. Antineutrophil cytoplasmic antibody-associated vasculitides: is it time to split up the group? Ann Rheum Dis. 2013; 72: 1273-1279
91. Mahr A, Katsahian S, Varet H et al. Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis. Ann Rheum Dis. 2013; 72: 1003-1010
92. Walsh M, Flossmann O, Berden A et al. Risk factors for relapse of antineu-trophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2012; 64: 542-548